China Representative Office opens
Filed with ASX · · 3 pages · English
Summary by 6ix AI
AdAlta Ltd. has announced the opening of a representative office in Shanghai, China, which has been approved by the Shanghai Municipal Administration for Market Regulation. This new office will allow AdAlta to engage local staff and contractors, enhancing its presence and collaboration in the Chinese market for cellular immunotherapies. The CEO emphasized that having a local presence is crucial for building relationships and managing collaborations effectively.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- US FDA grants EW-001 pre-IND meeting
- Oribiotech deal validates AdAlta manufacturing strategy
- BZDS1901 special access scheme launch in China
- EW-001 IIT study overall survival update
- 2 year survival milestone for EW-001 patient
Later from AdAlta
- EW-001 JDC milestone approvals
- RDTI receipt, Advanced Overseas Finding
- Quarterly Appendix 4C and Activities Report
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta